Celecoxib accelerates functional recovery after sciatic nerve crush in the rat^[*]

Abstract

The inflammatory response appears to be essential in the modulation of the degeneration and regeneration process after peripheral nerve injury. In injured nerves, cyclooxygenase-2 (COX-2) is strongly upregulated around the injury site, possibly playing a role in the regulation of the inflammatory response. In this study we investigated the effect of celecoxib, a COX-2 inhibitor, on functional recovery after sciatic nerve crush in rats. Unilateral sciatic nerve crush injury was performed on 10 male Wistar rats. Animals on the experimental group (n = 5) received celecoxib (10 mg/kg ip) immediately before the crush injury and daily for 7 days after the injury. Control group (n = 5) received normal saline at equal regimen. A sham group (n = 5), where sciatic nerve was exposed but not crushed, was also evaluated. Functional recovery was then assessed by calculating the sciatic functional index (SFI) on days 0,1,7,14 and 21 in all groups, and registering the day of motor and walking onset. In comparison with control group, celecoxib treatment (experimental group) had significant beneficial effects on SFI, with a significantly better score on day 7. Anti-inflammatory drug celecoxib should be considered in the treatment of peripheral nerve injuries, but further studies are needed to explain the mechanism of its neuroprotective effects.

^*This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

• References

• 1 Stoll G, Müller HW. Nerve injury, axonal degeneration and neural regeneration: basic insights. Brain Pathol 1999; 9 (2) 313-25 10219748
• 2 Richardson PM, Lu X. Inflammation and axonal regeneration. J Neurol 1994; 242 (Suppl 1) S57-60 10.1007/BF00939244
• 3 Hirschberg DL, Yoles E, Belkin M, Schwartz M. Inflammation after axonal injury has conflicting consequences for recovery of function: rescue of spared axons is impaired but regeneration is supported. J Neuroimmunol 1994; 50 (1) 9-16 10.1016/0165-5728(94)90209-7 8300861
• 4 Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003; 65: 153-9 10.1016/S0006-2952(02)01422-3 12504791
• 5 Muja N, DeVries GH. Prostaglandin E(2) and 6-keto-prostaglandin F(1alpha) production is elevated following traumatic injury to sciatic nerve. Glia 2004; 46 (2) 116-29 10.1002/glia.10349 15042580
• 6 Takahashi M, Kawaguchi M, Shimada K, Konishi N, Furuya H, Nakashima T. Cyclooxygenase-2 expression in Schwann cells and macrophages in the sciatic nerve after single spinal nerve injury in rats. Neurosci Lett 2004; 17, 363 (03) 203-6 10.1016/j.neulet.2004.03.040
• 7 Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002; 15 (6) 1037-47 10.1046/j.1460-9568.2002.01940.x 11918652
• 8 Ma W, Eisenach JC. Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 2003; 121 (3) 691-704 10.1016/S0306-4522(03)00495-0 14568029
• 9 Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004; 33 (1) 1-6 15124935
• 10 Miyamoto K, Oka N, Kawasaki T, Miyake S, Yamamura T, Akiguchi I. New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis. Muscle Nerve 2002; 25 (2) 280-2 10.1002/mus.10019 11870698
• 11 Sinn DI, Lee ST, Chu K, Jung KH, Song EC, Kim JM, Park DK, Kim M, Roh JK. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett 2007; 16, 411 (03) 238-242 10.1016/j.neulet.2006.10.050
• 12 Subbanna PK, Prasanna CG, Gunale BK, Tyagi MG. Acetyl salicylic acid augments functional recovery following sciatic nerve crush in mice. J Brachial Plex Peripher Nerve Inj 2007; 2: 3 1802865 17274829 10.1186/1749-7221-2-3
• 13 Bridge PM, Ball DJ, Mackinnon SE, Nakao Y, Brandt K, Hunter DA, Hertl C. Nerve crush injuries – a model for axonotmesis. Exp Neurol 1994; 127 (2) 284-90 10.1006/exnr.1994.1104 8033968
• 14 Hare GM, Evans PJ, Mackinnon SE, Best TJ, Bain JR, Szalai JP, Hunte DA. Walking track analysis: a long-term assessment of peripheral nerve recovery. Plast Reconstr Surg 1992; 89: 251-258 10.1097/00006534-199202000-00009 1732892
• 15 Carlton JM, Goldberg NH. Quantitating integrated muscle function following reinnervation. Surg Forum 1986; 37: 611-2
• 16 Gold BG, Storm-Dickerson T, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor. Neurol. Neurosci 1994; 6: 287-296
• 17 Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 2005; 4 (3) 335-40 10.2174/1568010054022051 16101543
• 18 Shamash S, Reichert F, Rotshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J Neurosci 2002; 22 (8) 3052-3060 11943808
• 19 Li H, Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 2008; 41 (1) 1-8 10.1016/j.cyto.2007.09.016 18068998
• 20 Funakoshi-Tago M, Shimizu T, Tago K, Nakamura M, Itoh H, Sonoda Y, Kasahara T. Celecoxib potently inhibits TNFalpha-induced nuclear translocation and activation of NF-kappaB. Biochem Pharmacol 2008; 76 (5) 662-671 10.1016/j.bcp.2008.06.015 18644347
• 21 Brück W. The role of macrophages in Wallerian degeneration. Brain Pathol 1997; 7 (2) 741-52 10.1111/j.1750-3639.1997.tb01060.x 9161725
• 22 Shin T, Lee Y, Sim KB. Involvement of cyclooxygenase-1 and -2 in the sciatic nerve of rats with experimental autoimmune neuritis. Immunol Invest 2003; 32 (3) 123-30 10.1081/IMM-120022973 12916703
• 23 Klegeris A, McGeer PL. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 2002; 23 (5) 787-94 10.1016/S0197-4580(02)00021-0 12392782